Additionally, in situ hybridization staining across patients and 138 ROIs also highlighted significantly higher numbers of IFNGR2+ cells in patients with COVID-19 than in non-LRTD controls but not between non-LRTD patients and patients with LRTD (Fig. 6d and Extended Data Fig. 8a–f). This evidence concerns the gene IFNGR2 and COVID-19.